A型肉毒杆菌神经毒素在一名难治性急迫性尿失禁患者中的应用，以促进膀胱癌的膀胱内治疗。
The use of botulinum neurotoxin type a in a patient with refractory urge incontinence to facilitate the intravesical treatment of bladder carcinoma.
作者信息
Fam Mina, Gilhooly Patricia
机构信息
Department of Surgery, Division of Urology, Rutgers New Jersey Medical School, Newark, NJ.
出版信息
Rev Urol. 2014;16(4):194-7.
Abstract
Intravesical Bacillus Calmette-Guérin (BCG) has become the preferred initial treatment after resection of high-grade T1 urothelial carcinoma and carcinoma in situ (CIS). We report the case of a patient with high-grade T1 urothelial carcinoma and CIS who was treated with intravesical BCG. Due to the patient's severe urge incontinence, however, the BCG solution leaked from the bladder immediately upon instillation. We describe our experience of using botulinum neurotoxin A intradetrusor injections to facilitate successful intravesical therapy by increasing bladder capacity to enable the BCG to remain in the patient's bladder for the appropriate treatment duration.
摘要
膀胱内灌注卡介苗（BCG）已成为高级别T1期尿路上皮癌和原位癌（CIS）切除术后的首选初始治疗方法。我们报告了一例接受膀胱内BCG治疗的高级别T1期尿路上皮癌和CIS患者的病例。然而，由于患者严重的急迫性尿失禁，BCG溶液在灌注后立即从膀胱漏出。我们描述了我们使用肉毒杆菌神经毒素A膀胱逼尿肌内注射的经验，通过增加膀胱容量，使BCG能够在患者膀胱内保留适当的治疗时间，从而促进膀胱内治疗的成功。
相似文献
1
2
[Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].[卡介苗膀胱内灌注治疗膀胱原位癌。岐阜卡介苗灌注治疗研究组]
Gan To Kagaku Ryoho. 1999 Oct;26(12):1869-73.
3
Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.卡介苗治疗失败的患者可能是非肌层浸润性膀胱癌，原因可能是泌尿科医生未能检测到上尿路和尿道的尿路上皮癌。
Eur Urol. 2014 Apr;65(4):825-31. doi: 10.1016/j.eururo.2013.09.049. Epub 2013 Oct 9.
4
Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.膀胱挛缩：卡介苗膀胱内灌注并发症的综述
Can J Urol. 2007 Dec;14(6):3745-9.
5
Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.膀胱原位癌且卡介苗治疗禁忌或失败的患者的膀胱内 VALrubicin。
Urol Oncol. 2013 Nov;31(8):1635-42. doi: 10.1016/j.urolonc.2012.04.010. Epub 2012 May 9.
6
Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer.辅助性膀胱内卡介苗治疗对高级别T1期膀胱癌患者的影响
Urol Int. 2016;96(2):136-41. doi: 10.1159/000443705. Epub 2016 Jan 21.
7
[Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].[卡介苗辅助膀胱内灌注治疗3级浅表性膀胱癌的结果]
Hinyokika Kiyo. 2004 Nov;50(11):767-71.
8
Association between the expression pattern of p16, pRb and p53 and the response to intravesical bacillus Calmette-Guerin therapy in patients with urothelial carcinoma in situ of the urinary bladder.膀胱癌原位癌患者 p16、pRb 和 p53 表达模式与膀胱内卡介苗治疗反应的关系。
Pathol Int. 2011 Aug;61(8):456-60. doi: 10.1111/j.1440-1827.2011.02694.x.
9
Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.膀胱内卡介苗治疗T1期3级膀胱移行细胞癌：57例患者的复发、进展及生存情况研究
J Urol. 2003 Jun;169(6):2110-2. doi: 10.1097/01.ju.0000066840.42991.4a.
10
Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.卡介苗免疫疗法治疗泌尿生殖系统癌症。
BJU Int. 2013 Aug;112(3):288-97. doi: 10.1111/j.1464-410X.2012.11754.x. Epub 2013 Mar 20.
引用本文的文献
1
Peripheral Mechanisms Underlying Bacillus Calmette-Guerin-Induced Lower Urinary Tract Symptoms (LUTS).卡介苗诱导下尿路症状（LUTS）的外周机制
Brain Sci. 2024 Nov 28;14(12):1203. doi: 10.3390/brainsci14121203.
本文引用的文献
1
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.卡介苗治疗失败后的高危非肌肉浸润性膀胱癌行膀胱内吉西他滨灌注治疗。
J Urol. 2013 Nov;190(5):1686-91. doi: 10.1016/j.juro.2013.04.120. Epub 2013 May 7.
2
Botulinum toxin treatment for overactive bladder: risk of urinary retention.肉毒杆菌毒素治疗膀胱过度活动症：尿潴留风险
Curr Urol Rep. 2008 Nov;9(6):445-51. doi: 10.1007/s11934-008-0077-1.
3
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.非肌层浸润性膀胱癌（Ta、T1和Tis期）管理指南：2007年更新版
J Urol. 2007 Dec;178(6):2314-30. doi: 10.1016/j.juro.2007.09.003.
4
Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.肉毒杆菌毒素A（保妥适）对神经源性逼尿肌过度活动/神经源性膀胱过度活动症成人患者进行膀胱逼尿肌内注射：一项系统文献综述
Eur Urol. 2008 Feb;53(2):275-87. doi: 10.1016/j.eururo.2007.10.013. Epub 2007 Oct 16.
5
[Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].[浅表性膀胱癌膀胱内卡介苗免疫治疗的作用机制]
Urologe A. 2006 May;45(5):629-33, 635-6. doi: 10.1007/s00120-006-1059-x.
6
Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes.A型肉毒杆菌神经毒素膀胱逼尿肌注射后神经源性与特发性逼尿肌过度活动患者的生活质量变化及其与下尿路症状和尿动力学变化的相关性
Eur Urol. 2006 Mar;49(3):528-35. doi: 10.1016/j.eururo.2005.12.012. Epub 2006 Jan 6.
7
Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.重度神经源性逼尿肌过度活动和尿失禁患者重复注射肉毒杆菌毒素A治疗逼尿肌的疗效
Eur Urol. 2005 May;47(5):653-9. doi: 10.1016/j.eururo.2004.11.009. Epub 2005 Jan 15.
8
The action of botulinum toxin on the neuro-muscular junction.肉毒杆菌毒素对神经肌肉接头的作用。
J Physiol. 1949 Aug;109(1-2):10-24. doi: 10.1113/jphysiol.1949.sp004364.
9
Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.肉毒杆菌A毒素治疗脊髓损伤患者逼尿肌反射亢进：抗胆碱能药物的新替代方案？初步结果。
J Urol. 2000 Sep;164(3 Pt 1):692-7. doi: 10.1097/00005392-200009010-00018.
10
Preventing progression and improving survival with BCG maintenance.通过卡介苗维持治疗预防疾病进展并提高生存率。
Eur Urol. 2000;37 Suppl 1:9-15. doi: 10.1159/000052376.
Zotero 插件